Compositions and methods for detection of ubiquitin-dependent cellular processes using engineered deubiquitinating enzymes
Through recombinant engineered deubiquitinase (DUB) catalyzing the modification and removal of ubiquitin chains, the diagnosis and treatment difficulties of transport defect mutations in hereditary ion channel disease are solved, and the anti-viral-dependent ubiquitination process is provided. Methods, effective treatment and control of hereditary ion channel disease and viral infection are achieved.
Patent Information
- Application Number
- CN202411135743.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-11-06
- Filing Date
- 2018-11-05
- Publication Date
- 2024-11-26
AI Technical Summary
Existing technologies are difficult to effectively diagnose and treat transport defect mutations in hereditary ion channel diseases, especially long QT syndrome and cystic fibrosis, as well as antiviral-dependent ubiquitination processes, lacking rapid and popularizable methods.
Developed a recombinantly engineered deubiquitinase (DUB) containing catalytic units, protein binding bodies and variable linkers for catalyzing the modification and removal of ubiquitin chains, and administering them to subjects in combination with nucleic acids to treat or alleviate genetics. STI and traffic defect mutations that can be treated with DUB are screened out.
Through recombinant engineered DUB, the surface density and total expression of the mutant channels can be restored, personalized treatment plans, and fight viral infections, significantly improving the ability to fight viruses.
Smart Images

Figure CN119020330A_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese invention patent application No. 201880080615.6, whose application date is November 5, 2018 and whose invention name is “Compositions and methods for detecting ubiquitin-dependent cellular processes using engineered deubiquitinating enzymes”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of U.S. Provisional Patent Application Serial No. 62 / 582,108, filed on November 6, 2017, the entire contents of which are incorporated herein by reference.
[0004] Government funding
[0005] This invention was made with government support under Grant No. HL122421 awarded by the National Institutes of Health. The government has certain rights in this invention. Field of the Invention
[0006] The present invention provides recombinantly engineered deubiquitinases (DUBs) and methods for treating or alleviating hereditary ion channel diseases in subjects, such as long QT syndrome, Brugada syndrome or cystic fibrosis, etc. Also provided herein is a method for screening for transport defect mutations that can be treated by the recombinantly engineered DUBs disclosed above from mutations that cause such hereditary ion channel diseases. Background of the Invention
[0008] Integral surface membrane proteins, including ion channels, transporters, and receptors, are essential for the survival and function of all cells. Therefore, the processes that control the surface abundance and composition of membrane proteins are key determinants of cell biology and physiology. Impaired surface trafficking of membrane proteins underlies a wide range of diseases from cystic fibrosis to cardiac arrhythmias (Gelman & Kopito, 2002; Anderson et al., 2014), motivating the need to better understand the fundamental mechanisms that control the surface density of membrane proteins. The surface reservoir of membrane proteins is regulated by a multi-layered maturation and trafficking process; starting with proper folding in the endoplasmic reticulum (ER), post-translational maturation in the Golgi apparatus, delivery to and continued optimization at the surface, and ultimately their removal and degradation in the lysosomes (MacGurn et al., 2012; Foot et al., 2017). A fundamental understanding of the mechanisms that control these different aspects of membrane protein fate is an important and heavily investigated area of research.
[0009] Ubiquitination is a powerful mechanism that can tune the functional expression of membrane proteins by regulating multiple steps in their life cycle. Ubiquitin is a 76-residue protein that can be covalently attached to lysine residues on polypeptide substrates through the sequential action of three enzymes: ubiquitin-activating enzyme (E1); ubiquitin-conjugating enzyme (E2); and ubiquitin ligase (E3), which catalyzes the transfer of ubiquitin to the substrate. The human genome encodes 2 E1, 37 E2, and > 600 E3 ubiquitin ligases. Ubiquitin contains 7 lysine residues (K6, K11, K27, K29, K33, K48, K63), which, together with its N-terminal methionine (Met1), can be used as secondary attachment sites to make a variety of polyubiquitin chains with different structures and functions (Komander, 2009) ( Figure 1 Ubiquitination is typically thought to target cytosolic proteins (substrate target proteins) for degradation by the proteasome (Hershko & Ciechanover, 1998). In contrast, ubiquitination of membrane proteins can lead to more subtle consequences, including regulation of protein trafficking / sorting, stability, and / or function (Komander, 2009; Foot et al., 2017). Ubiquitination has been implicated in genetic diseases such as cystic fibrosis, cardiac arrhythmias, epilepsy, and neuropathic pain, as well as in infectious diseases, promoting the pathogenic life cycle of multiple viral and bacterial pathogens.
[0010] Deubiquitinating enzymes (DUBs) are specialized isopeptidases that provide prominent properties for ubiquitin signaling by modifying and removing ubiquitin chains. There are over 100 human DUBs, including 6 distinct families: 1) the ubiquitin-specific protease (USP) family, 2) the ovarian tumor protease (OUT) family, 3) the ubiquitin C-terminal hydrolase (UCH) family, 4) the Josephin domain family (Josephin), 5) a novel DUB family containing a motif that interacts with ubiquitin (MINDY), and 6) the JAB1 / MPN / Mov34 metalloenzyme domain family (JAMM). Notably, the USP family is relatively promiscuous, hydrolyzing all ubiquitin linkages, in stark contrast to the OTU family, which contains multiple groups of enzymes with different linkage preferences. Linkage-specific DUBs have recently been purified and used in cell-free in vitro assays as a way to diagnose chain specificity prior to running target proteins on Western blots. In addition, purified linkage-specific DUBs have been used to sculpt more atypical ubiquitin chains for isolation and structural analysis.
[0011] Inherited channelopathies are rare diseases that encompass a broad spectrum of conditions in the nervous (epilepsy, migraine, neuropathic pain), cardiovascular (long QT syndrome, Brugada syndrome), respiratory (cystic fibrosis), endocrine (diabetes, hyperinsulinemic hypoglycemia), and urinary (Bartter syndrome, diabetes insipidus) systems. The rapidly expanding field of next-generation genome sequencing has revealed thousands of channel mutations with a variety of potential mechanisms. Understanding the underlying cause of loss of function is essential to treat each disease with a personalized strategy. These numerous inherited mutations result in defects in channel trafficking to the surface membrane. For example, cystic fibrosis, the most common fatal inherited disease in Caucasians, is caused by defects in the cystic fibrosis transmembrane conductance regulator (CFTR), a chloride channel. The most studied mutation (ΔF508) accounts for ~85% of all cases and causes channel misfolding and defects in ubiquitin-dependent trafficking. In the case of long QT syndrome, more than 500 mutations in two channels (KCNQ1, hERG) account for nearly 90% of all inherited cases. Transport defects in these two pathways are the mechanistic basis of most pathogenic mutations. It would be beneficial to establish a platform for high-throughput screening of such pathogenic mutations to diagnose the underlying pathological mechanisms. This diagnostic capability would provide information for the best treatment options for specific mutations, thereby developing personalized medicines for these rare diseases. The invention provided herein relates to such a platform. In addition, the present invention also provides new therapeutic opportunities for gene therapy and targeted correction of discovered ubiquitin-dependent transport defects.
[0012] Furthermore, the recent Ebola outbreak and the emergence of drug-resistant "superbugs" have revealed a growing need for rapid, scalable approaches to control and limit the spread of infection. Infectious pathogens exploit the ubiquitination process of host cells to spread and spread disease. In particular, viruses have been shown to utilize ubiquitin in every aspect of their life cycle: viral entry, replication, and budding. Across viral families, many viruses contain proteins with a PY motif that allows for the recruitment of host ubiquitin E3 ligases. The present invention exploits this conserved mechanism to provide a scalable approach to selectively target different infectious processes. In effect, the present invention is able to counter the viral reliance on ubiquitination required to sustain infection and provides a modular and transferable approach to combat emerging, life-threatening, and / or chronic infections. SUMMARY OF THE INVENTION
[0014] The present invention provides a recombinantly engineered deubiquitinase (DUB) comprising:
[0015] a) Catalytic unit;
[0016] b) protein binders; and
[0017] c) a variable linker between the catalytic unit and the protein binder.
[0018] The present invention also provides a method for treating or ameliorating the effects of an inherited ion channelopathy in a subject, comprising administering to the subject a nucleic acid encoding the above-described recombinantly engineered DUB.
[0019] The present invention also provides a method for screening out transport defect mutations that can be treated by the above-mentioned recombinant engineered DUB from mutations that cause hereditary ion channel diseases, which comprises the following steps:
[0020] a) Measure the surface density and / or total expression of mutant channels in cells expressing mutations causing inherited channelopathies;
[0021] b) If the surface density and / or total expression of the mutant channel is reduced relative to the wild-type (WT) channel, the ubiquitination status of the mutant channel is determined;
[0022] c) based on the ubiquitination status of the mutant channel, selecting and co-expressing the above recombinantly engineered DUB with the mutation, and then measuring the surface density and / or total expression of the mutant channel in cells with co-expression; and
[0023] d) If the surface density and / or total expression of the mutant channel is restored relative to the WT channel in step (c), the mutation is identified as treatable.
[0024] The present invention also provides a method for treating or ameliorating the effects of acute / chronic viral infection in a subject, comprising administering to the subject a nucleic acid encoding the above-mentioned recombinant engineered DUB.
[0025] The present invention also provides a recombinant expression vector comprising a nucleic acid encoding the above-mentioned recombinantly engineered DUB, and also provides a cell transformed with the vector. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] The application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0027] The following drawings constitute part of this specification and are included to further illustrate some aspects of the present invention. The present invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0028] Figure 1 The structure of ubiquitin is shown, including seven lysine residues (K6, K11, K27, K29, K33, K48, K63) and its N-terminal methionine (Met1).
[0029] Figure 2A graphic showing the engineered nanoDUB designed to rescue Nedd4-2-mediated reduction in endogenous Q1 ubiquitination and surface expression.
[0030] Figure 3A and 3B The effects of nanoDUB on Nedd4-2-mediated effects on Q1 expression and ubiquitination are shown.
[0031] Figure 3C and 3D Shown is the effect of nanoDUB on surface and total Q1 under basal conditions.
[0032] Figure 3E and 3F Shown are the effects of nanoDUB on surface and total Q1 in the presence of Nedd4-2 expression.
[0033] Figure 4A Graphic showing different LQT1 mutations.
[0034] Figure 4B Flow cytometry dot plots showing the surface density of WT Q1.
[0035] Figure 4C and 4D are flow cytometry dot plots showing differential rescue of surface density of two LQT1 mutants (G589D in 4C and V524G in 4D) by nanoOTUD1.
[0036] Figure 5 Shown are the effects of low temperature and nanoOTUD1 on the surface (upper panel) and total (lower panel) expression of HERG in WT and LQT2 mutants. DETAILED DESCRIPTION OF THE INVENTION
[0038] One embodiment of the present invention is a recombinantly engineered deubiquitinase (DUB) comprising:
[0039] a) Catalytic unit;
[0040] b) protein binders; and
[0041] c) A variable linker between the catalytic unit and the protein binder.
[0042] In one aspect of this embodiment, the catalytic unit of the recombinant engineered DUB is selective for all ubiquitin linkage types. In another aspect of this embodiment, the catalytic unit is selective for a specific ubiquitin linkage type.
[0043] According to this embodiment, the catalytic unit comprises a catalytic domain of a deubiquitinase selected from the group consisting of the ubiquitin-specific protease (USP) family, the ovarian tumor protease (OTU) family, the ubiquitin C-terminal hydrolase (UCH) family, the Josephin domain family (Josephin), a novel DUB family containing a motif that interacts with ubiquitin (MINDY), and the JAB1 / MPN / Mov34 metalloenzyme domain family (JAMM).
[0044] According to some embodiments, the catalytic unit comprises a catalytic domain of a deubiquitinating enzyme from the USP family. In one embodiment, the catalytic unit comprises the catalytic domain of USP21.
[0045] According to some embodiments, the catalytic unit comprises a catalytic domain of a deubiquitinase from the OTU family. In one embodiment, the catalytic unit comprises the catalytic domain of OTUD1. In one embodiment, the catalytic unit comprises the catalytic domain of OTUD4. In one embodiment, the catalytic unit comprises the catalytic domain of Cezanne. In one embodiment, the catalytic unit comprises the catalytic domain of TRABID. In one embodiment, the catalytic unit comprises the catalytic domain of OTULIN.
[0046] According to this embodiment, the protein binder of the recombinant engineered DUB is selected from intrabody fragments, scFv, nanobodies, antibody mimetics, monoclonal antibodies, DARPins, lipocalins and targeting sequences. In one embodiment, the protein binder is a vhh4 nanobody.
[0047] In certain embodiments, the catalytic unit is the catalytic domain of USP21, and the protein binder is a vhh4 nanobody, and the resulting recombinant engineered deubiquitinase (nanoUSP21) is capable of non-selectively eliminating all types of connections. In certain embodiments, the catalytic unit is the catalytic domain of OTUD1, and the protein binder is a vhh4 nanobody, and the resulting recombinant engineered deubiquitinase (nanoOTUD1) is capable of selectively eliminating K63 connections. In certain embodiments, the catalytic unit is the catalytic domain of OTUD4, and the protein binder is a vhh4 nanobody, and the resulting recombinant engineered deubiquitinase (nanoOTUD4) is capable of selectively eliminating K48 connections. In certain embodiments, the catalytic unit is the catalytic domain of Cezanne, and the protein binder is a vhh4 nanobody, and the resulting recombinant engineered deubiquitinase (nanoCezanne) is capable of selectively eliminating K11 connections. In certain embodiments, the catalytic unit is the catalytic domain of TRABID, and the protein binder is a vhh4 nanobody, and the resulting recombinant engineered deubiquitinase (nanoTRABID) is capable of selectively eliminating K29 and / or K33 connections. In certain embodiments, the catalytic unit is the catalytic domain of OTULIN, and the protein binder is a vhh4 nanobody, and the resulting recombinant engineered deubiquitinase (nanoOTULIN) is capable of selectively eliminating Met1 connections. As used herein, "capable" means that the object, such as a recombinant engineered DUB, has complete functionality and, under appropriate conditions, will perform the function described.
[0048] Another embodiment of the invention is a method of treating or ameliorating the effects of an inherited ion channelopathy in a subject, comprising administering to the subject a nucleic acid encoding a recombinantly engineered DUB disclosed herein above.
[0049] As used herein, the term "inherited channelopathy" refers to a rare disease covering a wide range of conditions in the nervous system, cardiovascular system, respiratory system, endocrine system, and urinary system. In the present invention, "inherited channelopathy" includes, but is not limited to, epilepsy, migraine, neuropathic pain, arrhythmia, long QT syndrome, Brugada syndrome, cystic fibrosis, diabetes, hyperinsulinemia hypoglycemia, Bartter syndrome, and diabetes insipidus. In a preferred embodiment, the inherited channelopathy is long QT syndrome.
[0050] In a preferred embodiment, the inherited ion channelopathy is long QT syndrome and the recombinantly engineered deubiquitinase is nanoOTUD1.
[0051] As used herein, the terms "treat," "treating," "treatment," and grammatical variations thereof refer to the subjecting of an individual subject to a procedure, regimen, process, or remedy in which a physiological response or outcome is desired in the subject (e.g., a patient). However, since every subject treated may not respond to a particular treatment procedure, regimen, process, or remedy, treatment does not require that every subject or population of subjects (e.g., a patient population) achieve the desired physiological response or outcome. Thus, a given subject or population of subjects, such as a patient population, may not respond or respond inadequately to a treatment.
[0052] As used herein, the terms "mitigate," "relieve," and grammatical variations thereof refer to a reduction in the severity of disease symptoms in a subject, preferably a human.
[0053] As used herein, "administering", "administering" and variants thereof refer to the introduction of a composition, such as a synthetic membrane-receptor complex or a medicament, into a subject, and include simultaneous and sequential introduction of the composition or agent. The composition or agent is introduced into the subject by any suitable route, including oral, intrapulmonary, intranasal, parenteral (intravenous, intramuscular, intraperitoneal or subcutaneous), rectal, intralymphatic or topical. Administration includes self-administration and administration by others. Suitable routes of administration enable the composition or medicament to achieve its intended function. For example, if the suitable route is intravenous, the composition is administered by introducing the composition or medicament into the subject's vein. Administration can be performed by any suitable route.
[0054] As used herein, a "subject" is a mammal, preferably a human. In addition to humans, categories of mammals within the scope of the present invention include, for example, farm animals, domestic animals, laboratory animals, etc. Some examples of farm animals include cows, pigs, horses, goats, etc. Some examples of domestic animals include dogs, cats, etc. Some examples of laboratory animals include primates, rats, mice, rabbits, guinea pigs, etc.
[0055] Another embodiment of the present invention is a method for screening mutations causing inherited ion channel diseases for trafficking defective mutations that can be treated by the recombinantly engineered DUBs described herein before, comprising the steps of:
[0056] a) Measure the surface density and / or total expression of mutant channels in cells expressing mutations causing inherited channelopathies;
[0057] b) If the surface density and / or total expression of the mutant channel is reduced relative to the wild-type (WT) channel, the ubiquitination status of the mutant channel is determined;
[0058] c) based on the ubiquitination status of the mutant channel, selecting and co-expressing the recombinant engineered DUB of claim 1 with the mutation, and then measuring the surface density and / or total expression of the mutant channel in cells with the co-expression; and
[0059] d) If the surface density and / or total expression of the mutant channel is restored relative to the WT channel in step (c), the mutation is identified as treatable.
[0060] Another embodiment of the invention is a method of treating or ameliorating the effects of an acute / chronic viral infection in a subject, comprising administering to the subject a nucleic acid encoding a recombinant engineered DUB as previously disclosed herein.
[0061] In some aspects of this and other embodiments, the subject is a mammal. Preferably, the mammal is selected from humans, primates, farm animals, and domestic animals. More preferably, the mammal is a human.
[0062] Another embodiment of the present invention is a recombinant expression vector comprising a nucleic acid encoding a recombinantly engineered DUB as previously disclosed herein.
[0063] Another embodiment of the present invention is a cell transformed with the vector disclosed above.
[0064] Additional Definitions
[0065] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that have similar functions to naturally occurring amino acids. Naturally occurring amino acids are amino acids encoded by the genetic code, as well as those amino acids that are later modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. "Amino acid analogs" refer to compounds having the same basic chemical structure as naturally occurring amino acids, such as carbon bound to hydrogen, carboxyl, amino, and R groups, such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Imino acids, such as proline, are also within the scope of "amino acids" as used herein. "Amino acid mimetics" refer to chemical compounds having a structure different from the general chemical structure of amino acids but having similar functions to naturally occurring amino acids.
[0066] As used herein, the terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of the corresponding naturally occurring amino acids, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymers.
[0067] As used herein, "nucleic acid" or "oligonucleotide" or "polynucleotide" refers to at least two nucleotides covalently linked together. Many variants of nucleic acids can be used for the same purpose as a given nucleic acid. Therefore, nucleic acids also include substantially identical nucleic acids and their complements.
[0068] Nucleic acids may be single-stranded or double-stranded, or may contain portions of double-stranded and single-stranded sequences. Nucleic acids may be DNA (genomic and cDNA), RNA, or hybrids, wherein nucleic acids may contain a combination of deoxyribonucleotides and ribonucleotides, and a combination of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, and isoguanine. Nucleic acids may be synthesized as single-stranded molecules or expressed in cells (in vitro or in vivo) using synthetic genes. Nucleic acids may be obtained by chemical synthesis methods or by recombinant methods.
[0069] The nucleic acid can also be RNA, such as mRNA, tRNA, short hairpin RNA (shRNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), transcriptional gene silencing RNA (ptgsRNA), Piwi-interacting RNA, pri-miRNA, pre-miRNA, micro RNA (miRNA) or anti-miRNA.
[0070] As used herein, the term "antibody" encompasses immunoglobulins and fragments thereof that are naturally or partially or completely synthetically produced. The term also encompasses any protein having a binding domain homologous to an immunoglobulin binding domain. These proteins may be derived from natural sources, or partially or completely synthetically produced. "Antibodies" also include polypeptides that specifically bind to and recognize antigens comprising framework regions from immunoglobulin genes or fragments thereof. The use of the term antibody is intended to include whole antibodies, polyclonal, monoclonal and recombinant antibodies, fragments thereof, and also includes single-chain antibodies, humanized antibodies; mouse antibodies; chimeric, mouse-human, mouse-primate, primate-human monoclonal antibodies, anti-idiotypic antibodies, antibody fragments, such as, for example, scFv, (scFv)2, Fab, Fab', and F(ab')2, F(ab1)2, Fv, dAb, and Fd fragments, double antibodies, nanobodies, and antibody-related polypeptides. Antibodies include bispecific antibodies and multispecific antibodies, as long as they exhibit the desired biological activity or function.
[0071] The term "antigen binding fragment" as used herein refers to a fragment of a complete immunoglobulin, and any part of a polypeptide, which contains an antigen binding region with the ability to specifically bind to an antigen. For example, an antigen binding fragment may be a F(ab')2 fragment, a Fab' fragment, a Fab fragment, a Fv fragment, or a scFv fragment, but is not limited thereto. The Fab fragment has an antigen binding site and contains the variable regions of the light chain and the heavy chain, the constant region of the light chain, and the first constant region CH1 of the heavy chain. The difference between the Fab' fragment and the Fab fragment is that the Fab' fragment additionally contains the hinge region of the heavy chain, and includes at least one cysteine residue at the C-terminus of the heavy chain CH1 region. When the cysteine residues of the Fab' fragment are connected by disulfide bonds in the hinge region, a F(ab')2 fragment is produced. The Fv fragment is the smallest antibody fragment having only the heavy chain variable region and the light chain variable region, and the recombinant technology for producing the Fv fragment is well known in the art. The double-chain Fv fragment may have a structure in which the heavy chain variable region is connected to the light chain variable region by a non-covalent bond. Single-chain Fv (scFv) fragments can generally have a dimer structure like double-chain Fv fragments, in which the heavy chain variable region is covalently bound to the light chain variable region through a peptide linker, or the heavy chain and light chain variable regions are directly connected to each other at their C-termini. Antigen-binding fragments can be obtained using proteases (for example, whole antibodies are digested with papain to obtain Fab fragments, and digested with pepsin to obtain F(ab')2 fragments), and can be prepared by genetic recombination technology. The dAb fragment consists of the VH domain. Single-chain antibody molecules can contain polymers with multiple individual molecules, such as dimers, trimers or other polymers.
[0072] As used herein, "vector" refers to a component capable of directing the expression of a desired protein. The vector must include a transcription promoter element operably linked to one or more target genes. The vector can be composed of deoxyribonucleic acid ("DNA"), ribonucleic acid ("RNA"), or a combination of the two (e.g., DNA-RNA chimeras). Optionally, the vector may include a polyadenylation sequence, one or more restriction sites, and one or more selectable markers, such as neomycin phosphotransferase or hygromycin phosphotransferase. In addition, depending on the selected host cell and the vector used, other genetic elements such as an origin of replication, additional nucleic acid restriction sites, enhancers, sequences that confer transcriptional inducibility, and selectable markers may also be incorporated into the vectors described herein.
[0073] As used herein, the term "cell", "host cell" or "recombinant host cell" refers to a host cell engineered to express a desired recombinant protein. The method for producing a recombinant host cell is well known in the art. For example, see Sambrook et al. (MOLECULAR CLONING: A LABORATORY MANUAL (Sambrook et al., ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989), Ausubel et al. (CURRENT PROTOCOLS IN MOLECULAR BIOLOGY Ausubel et al., ed., John Wiley & Sons, New York, 1987). In the present invention, a host cell is transformed with a vector as described herein.
[0074] The recombinant host cell used herein can be any host cell used for recombinant protein production, including but not limited to bacterial, yeast, insect and mammalian cell lines.
[0075] As used herein, the terms "increase," "enhance," "stimulate," and / or "induce" (and similar terms) generally refer to an action that directly or indirectly improves or increases the concentration, level, function, activity, or behavior relative to natural, expected, or average or relative to control conditions.
[0076] As used herein, the terms "inhibit," "suppress," "reduce," "interfere with," and / or "reduce" (and similar terms) generally refer to an action that directly or indirectly decreases the concentration, level, function, activity, or behavior relative to native, expected, or average or relative to a control condition.
[0077] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0078] For the recitation of numerical ranges herein, each intermediate number with the same degree of precision is expressly included. For example, for the range of 6-9, in addition to 6 and 9, the numbers 7 and 8 are also included, and for the range of 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 and 7.0 are expressly included. Example
[0079] The following examples are provided to further illustrate some aspects of the present invention. These examples are merely illustrative and are not intended to limit the scope of the present invention in any way.
[0080] Example 1
[0081] Materials and methods
[0082] Molecular biology and plasmid vector cloning
[0083] A custom bicistronic vector (xx-P2A-CFP) was synthesized in the pUC57 vector, in which the coding sequence for the P2A peptide was sandwiched between an upstream multiple cloning site and enhanced cyan fluorescent protein (CFP) (Genewiz). The xx-P2A-CFP fragment was amplified by PCR and cloned into the PiggyBac CMV mammalian expression vector (SystemBiosciences) using NheI / NotI sites. To generate nano-xx-P2A-CFP, we PCR amplified the coding sequence of the GFP nanobody (vhhGFP4) and cloned it into xx-P2A-CFP using NheI / AflII sites. The nanoDUB construct was created by gene synthesis (Genewiz) and features the coding sequence of the GFP nanobody (vhhGFP4) in frame with the catalytic domain of a selected deubiquitinase (DUB) (Kubala et al., 2010), separated by a flexible GSG linker. This fragment was PCR amplified and cloned into the xx-P2A-CFP vector using the NheI / AflII sites.
[0084] Slmb:nano-P2A-CFP was derived from pcDNA3_NSlmb-vhhGFP4 (Addgene #35579) (Caussinus et al., 2011). We PCR amplified the NSlmb-vhhGFP4 fragment and cloned it into xx-P2A-CFP using NheI / AflII sites. To generate nanoMDM2, we PCR amplified the RING domain (residues 432-491) and cloned this fragment into nano-xx-P2A-CFP using AscI / AflII sites. To create nanoNEDD4L, we first PCR amplified the HECT domain (residues 640-975) of NEDD4L (PCI_NEDD4LL; Addgene #27000) and cloned this fragment into nano-xx-P2A-CFP using AscI / AflII sites. The resulting construct nanoNEDD4L-P2A-CFP expressed poorly, so we swapped the positions of nanoNEDD4L and CFP. We first generated CFP-P2A-xx and then PCR amplified nanoNEDD4L. The resulting fragment was cloned into CFP-P2A-xx using the BglII / NotI sites.
[0085] KCNQ1 / E1 constructs were prepared as described previously (Aromolaran et al., 2014). Briefly, enhanced yellow fluorescent protein (EYFP) was fused in frame to the C termini of KCNQ1 and KCNE1 using overlap extension PCR. A 13-residue bungarotoxin binding site (BBS; TGGCGGTACTACGAGAGCAGCCTGGAGCCCTACCCCGAC) (Sekine-Aizawa & Huganir, 2004; Yang et al., 2010) was introduced between residues 148–149 in the extracellular S1–S2 loop of KCNQ1 using the Quik-Change Lightning site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions.
[0086] The nanoDUB construct (DUB-P2A-CFP-P2A:nano) was created in three parts. First, the DUB catalytic domain was amplified by PCR and the amplified fragment was cloned into the xx-P2A-CFP vector using AscI / AflII sites to create DUB-P2A-CFP. Second, we used overlap extension PCR to create the P2A:nano cassette, which was then cloned downstream of CFP in the DUB-P2A-CFP construct using BglII / NotI sites to generate DUB-P2A-CFP-P2A-nano.
[0087] Generation of adenoviral vectors
[0088] Low-passage human embryonic kidney (HEK293) cells were cultured in DMEM supplemented with 8% fetal bovine serum (FBS) and 100 mg / mL penicillin-streptomycin at 37°C. Transfection of HEK293 cells was accomplished using the calcium phosphate precipitation method. Briefly, plasmid DNA was mixed with 62 µL of 2.5M CaCl2 and sterile deionized water (final volume 500 µL). The mixture was added dropwise with constant tapping to 500 µL of 2x Hepes-buffered saline, which contains (in mM): Hepes 50, NaCl 280, Na2HPO4 1.5, pH 7.09. The resulting DNA-calcium phosphate mixture was incubated at room temperature for 20 minutes and then added dropwise to HEK293 cells (60-80% confluency). After 4-6 hours, the cells were precipitated with Ca-free PBS. 2+ Cells were washed with phosphate-buffered saline and maintained in supplemented DMEM.
[0089] Chinese hamster ovary (CHO) cells were cultured in Kaighn's modified Ham's F-12K (ATCC) supplemented with 8% FBS and 100 mg / mL penicillin-streptomycin at 37°C. CHO cells were transiently transfected with the desired constructs using X-tremeGENE HP (DNA / reagent ratio 1:2) according to the manufacturer's instructions (Roche) in 35-mm tissue culture dishes—KCNQ1 (0.5 µg), KCNE1 (0.5 µg), and nano-P2A-CFP (0.5 µg) and nanoDUB-P2A-CFP (0.5 µg).
[0090] Primary cultures of adult rat cardiac ventricular cells were prepared as previously described (Colecraft et al., 2002; Subramanyam et al., 2013) in accordance with the guidelines of the Columbia University Animal Care and Use Committee. Adult male Sprague–Dawley rats were euthanized with an overdose of isoflurane. Hearts were dissected and ventricular myocytes were isolated by enzymatic digestion with 1.7 mg Liberase-TM enzyme mix (Roche) using a Langendorff perfusion apparatus. Healthy rod myocytes were cultured in Medium 199 (Life Technologies) supplemented with (in mM) carnitine (5), creatine (5), taurine (5), penicillin-streptomycin-glutamine (0.5%, Life Technologies), and 5% (vol / vol) FBS (Life Technologies) to promote attachment to culture dishes. After 5 h, the medium was switched to Medium 199 containing 1% (vol / vol) serum but supplemented as described above. The cultures were maintained in a humidified incubator at 37°C and 5% CO2.
[0091] Flow cytometric determination of total and surface Q1 channels
[0092] Cell surface and total ion channel pools were determined by flow cytometry in live, transfected HEK293 cells as described previously (Yang et al., 2010; Aromolaran et al., 2014). Briefly, 48 h after transfection, cells cultured in 6-well plates were incubated with Ca-containing 2+ and Mg 2+ HEK293 cells were gently washed with ice-cold PBS (in mM: 0.9 CaCl2, 0.49 MgCl2, pH 7.4) and then incubated in blocking medium (DMEM with 3% BSA) at 4°C for 30 min. HEK293 cells were then incubated with α-bungarotoxin conjugated with 1 µM Alexa Fluor 647 (BTX-647; Life Technologies) in DMEM / 3% BSA on a shaker at 4°C for 1 h, followed by PBS (with Ca 2+ and Mg 2+ ) and washed three times. The cells were gently harvested in a Ca-free 2+ The cells were then incubated in PBS and assayed by flow cytometry using a BD LSRII cell analyzer (BD Biosciences, San Jose, CA, USA). CFP- and YFP-tagged proteins were excited at 407 and 488 nm, respectively, and Alexa Fluor 647 was excited at 633 nm.
[0093] Optical pulse-chase assays were performed on live, transfected HEK293 cells to monitor the rate of channel forward transport and internalization. Cells were placed at 4°C to arrest transport and incubated with Ca-containing 2+ and Mg 2+ For forward transport experiments, cells were incubated with 5 µM untagged BTX in DMEM / 3% BSA at 4°C for 1 hour to block surface channels and then washed twice with Ca 2+ and Mg 2+ The cells were washed three times with PBS. The cells were incubated with DMEM / 3% BSA and placed at 37°C for different time intervals (0, 5, 10, 20, 40, 60 min) to restore transport. The cells were then returned to 4°C and the newly delivered channels were labeled with 1 µM BTX-647 in DMEM / 3% BSA for 1 h. Finally, the cells were incubated with Ca 2+ and Mg 2+ Wash 3 times with PBS and gently harvest in Ca-free 2+ For internalization experiments, cells were incubated in DMEM / 3% BSA blocking medium at 4°C for 30 min, followed by a pulse of 1 µM biotinylated α-bungarotoxin (BTX-biotin; Life Technologies) at 4°C with gentle shaking for 1 h. 2+ and Mg 2+ The cells were washed three times in PBS and placed in DMEM / 3% BSA at 37°C for different time intervals (0, 5, 10, 20, 40, 60 min) to resume transport. The cells were returned to 4°C, washed once with PBS, and the channels that remained on the surface were labeled with streptavidin-conjugated Alexa Fluor (Life Technologies). Finally, the cells were incubated with Ca-containing 2+ and Mg 2+ Wash twice more with PBS and harvest in Ca-free 2+ of PBS and measured by flow cytometry.
[0094] Confocal detection of total and surface Q1 expression in cardiomyocytes
[0095] At 48 h post-infection, adult rat cardiomyocytes cultured on 35 mm MatTek dishes (MatTek Corporation) were gently washed with M199 medium (containing 0.9 mM CaCl2, 0.49 mM MgCl2, pH 7.4) and fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature (RT). Cardiomyocytes were washed three times with PBS and incubated in blocking medium (M199 containing 3% BSA) for 30 min. Cardiomyocytes were then incubated with 1 µM BTX-biotin in M199 / 3% BSA for 1 h at RT and then washed three times with PBS to remove unbound biotinylated BTX. Cells were then incubated with 10 nM quantum dots 655 (QD655; Life Technologies) conjugated with streptavidin for 1 h in the dark at 4°C, washed three times with PBS, and imaged for scanning confocal microscopy using a Nikon Ti Eclipse inverted microscope.
[0096] Electrophysiology
[0097] For potassium channel measurements, whole-cell membrane currents in CHO cells were recorded at room temperature using an EPC-10 patch clamp amplifier (HEKA Electronics) controlled by PatchMaster software (HEKA). Coverslips with adherent CHO cells were placed on the glass bottom of a recording chamber (volume 0.7–1 mL) mounted on an inverted Nikon Eclipse Ti-U microscope stage. Micropipettes were made of 1.5-mm thin-walled glass and fire-polished. The internal solution contained (in mM): 133 KCl, 0.4 GTP, 10 EGTA, 1 MgSO4, 5 K2ATP, 0.5 CaCl2, and 10 HEPES (pH 7.2). The external solution contained (in mM): 147 NaCl, 4 KCl, 2 CaCl2, and 10 HEPES (pH 7.4). The resistance of the pipette was typically 1.5 MΩ when filled with the internal solution. I–V curves were generated by a series of step depolarizations (from -40 to +100 mV in 10 mV steps from a holding potential of -50 mV). Currents were sampled at 20 kHz and filtered at 5 kHz. Traces were acquired with a repetition interval of 10 s.
[0098] For calcium channel measurements, whole-cell recordings were performed at room temperature in HEK293 cells. The internal solution contained (mM): 135 Cs methanesulfonate, 5 CsCl, 5 EGTA, 1 MgCl2, 4 MgATP, 10 HEPES (pH 7.2). The external solution contained (mM): 140 tetraethylammonium methanesulfonate, 5 BaCl2, 10 HEPES (pH 7.4). Leak and capacitive currents were subtracted using a P / 4 scheme. IV curves were generated by a series of stepwise depolarizations (from -60 to +100 mV in 10 mV steps from a holding potential of -90 mV). Currents were sampled at 20 kHz and filtered at 5 kHz. Traces were acquired with a repetition interval of 10 s.
[0099] Immunoprecipitation and Western blotting
[0100] HEK293 cells were cultured without Ca 2+The cells were washed once with PBS, harvested, and resuspended in RIPA lysis buffer containing (in mM) Tris (20, pH 7.4), EDTA (1), NaCl (150), 0.1% (wt / vol) SDS, 1% Triton X-100, 1% sodium deoxycholate, and supplemented with protease inhibitor cocktail (10 µL / mL, Sigma-Aldrich), PMSF (1 mM, Sigma-Aldrich), and PR-619 deubiquitinase inhibitor (50 µM, LifeSensors). Lysates were prepared by incubation at 4°C for 1 hour (with occasional vortexing) and clarified by centrifugation (10,000 × g, 10 min, 4°C). The supernatant was transferred to a new tube and an aliquot was removed for quantification of total protein concentration using the bicinchoninic acid protein assessment kit (Pierce Technologies). Lysates were precleared by incubation with 10 µL Protein A / G Sepharose beads (Rockland) at 4°C for 40 min and then incubated with 0.75 µg anti-Q1 (Alomone) at 4°C for 1 h. Equal amounts of total protein were added to a spin column containing 25 µL Protein A / G Sepharose beads and tumbled overnight at 4°C. Immunoprecipitates were washed 3–5 times with RIPA buffer, pelleted by centrifugation at 500 × g, eluted with 40 µL heated sample buffer [50 mM Tris, 10% (vol / vol) glycerol, 2% SDS, 100 mM DTT, and 0.2 mg / mL bromophenol blue], and boiled (55°C, 15 min). Proteins were resolved on 4–12% Bis·Tris gradient precast gels (Life Technologies) in Mops-SDS running buffer (Life Technologies) at 200 V constant voltage for approximately 1 h. 10 µL of PageRuler Plus prestained protein ladder (10–250 kDa, Thermo Fisher) was loaded next to the sample. The protein bands were transferred to nitrocellulose membranes in transfer buffer (25 mM Tris pH 8.3, 192 mM glycine, 15% (vol / vol) methanol and 0.1% SDS) by pool transfer (3.5 h, 4°C, 30 V constant). The membranes were blocked with 5% skim milk (BioRad) in tris-buffered saline-Tween (TBS-T) (25 mM Tris pH 7.4, 150 mM NaCl and 0.1% Tween-20) for 1 h at room temperature and then incubated with primary antibody (anti-Q1, Alomone) in blocking solution overnight at 4°C.The blot was washed three times with TBS-T for 10 minutes each and then incubated with a secondary antibody conjugated with horseradish peroxidase for 1 hour at room temperature. After washing in TBS-T, the blot was developed with a chemiluminescent detection kit (Pierce Technologies) and then viewed on a gel imager. The membrane was then stripped with harsh stripping buffer (2% SDS, 62mM Tris pH 6.8, 0.8% β-mercaptoethanol) at 50°C for 30 minutes, rinsed under running water for 2 minutes, and washed with TBST (3x, 10 minutes). The membrane was pretreated with 0.5% glutaraldehyde and reblotted with anti-ubiquitin (VU1, LifeSensors) according to the manufacturer's instructions.
[0101] Data and statistical analysis
[0102] Data were analyzed offline using FloJo, PulseFit (HEKA), Microsoft Excel, Origin, and GraphPad Prism software. Statistical analysis was performed in Origin or GraphPad Prism using built-in functions. For comparisons between two groups, Student's t test was used to determine statistically significant differences between means (P < 0.05). Data are expressed as mean ± sem.
[0103] Example 2
[0104] Design, efficacy and unique functional effects of different engineered nanoDUBs on Q1
[0105] Similar to E3 ligases, some wild-type DUBs have a modular structure in which the catalytic and substrate targeting domains are separate. To develop nanoDUBs, we fused the catalytic domains of different DUBs to the vhh4 GFP nanobody by following the method described in Example 1. We have generated three different nanoDUBs - nanoUSP21 (non-selective cleavage of all ubiquitin chain types), nanoOTUD1 (specific for K63 chains), and nanoOTUD4 (specific for K48 chains).
[0106] To determine the efficacy of the generated nanoDUBs ( Figure 2 ), we first assessed their ability to reverse Nedd4-2-mediated ubiquitination of Q1-YFP. In pull-down Western blots, co-expression of WT Nedd4-2 resulted in a significant decrease in Q1-YFP expression compared to controls, consistent with decreased channel stability ( Figure 3ADespite the decrease in Q1-YFP protein, the overall level of channel ubiquitination was similar between control and each Nedd4-2 transfected cells, indicating that relative channel ubiquitination was stronger in the latter groups ( Figure 3B ). Reassuringly, co-expression with nanoOTUD1 or nanoUSP21 rescued the expression level of Q1-YFP ( Figure 3A ) and significantly reduced the ubiquitination of the channel ( Figure 3B Consistent with the view that USP21 is a non-selective DUB capable of hydrolyzing all ubiquitin chains, nanoUSP21 eliminated all ubiquitination of Q1-YFP ( Figure 3B In contrast, nanoOTUD1 only partially eliminated ubiquitin from Q1-YFP ( Figure 3B ), consistent with the idea that this nanoDUB eradicates only the K63 chain.
[0107] To find out the types of chains presented and their functions and potential alterations upon Nedd4-2 co-expression, we combined nanoDUB with our high-throughput flow cytometry assay ( Figure 3C -F). Co-expression of nanoOTUD1 (K63 eliminated) with BBS-Q1-YFP slightly reduced surface density and slightly increased total channel expression ( Figure 3C , D; cyan trace). Similarly, nanoUSP21 (eliminating all ubiquitin) modestly reduced surface density (but to a greater extent than nanoOTUD1) while slightly enhancing total channel expression ( Figure 3C , D; green trace). Most surprisingly, OTUD4 (K48 ablation) significantly reduced channel surface density and modestly reduced total expression ( Figure 3C , D; red trace). These preliminary results suggest some far-reaching conclusions, namely that under basal conditions: 1) K48 polyubiquitin chains are important for stabilizing Q1 on the cell surface; 2) ubiquitination is not a major determinant of channel stability (ablation of ubiquitination by nanoUSP21 only slightly increased channel expression); and 3) ubiquitin regulation of channel surface density and stability are discrete events (nanoUSP21 and nanoOTUD1 have opposite effects on these two parameters).
[0108] The effects of nanoDUB in cells co-expressing BBS-Q1-YFP and Nedd4-2 strengthen these conclusions and provide new insights ( Figure 3E , F). Under these conditions, nanoOTUD1 prevented the significant decrease in Nedd4-2-induced channel surface density and total expression ( Figure 3E, F; cyan vs. black traces); nanoOTUD4 further reduced channel surface density and total expression beyond the levels achieved by Nedd4-2 ( Figure 3E , F; red trace); nanoUSP21 had a moderate effect on channel surface density (partial rescue) but completely rescued total expression ( Figure 3E , F; green trace). From these data we can conclude that: 1) Nedd4-2 primarily mediates K63 ubiquitination of Q1 (because OTUD1 reverses the effect of Nedd4-2); 2) K63 chains promote Q1 degradation, whereas K48 chains stabilize the channel; 3) K63 chains reduce channel surface density, whereas K48 stabilizes the surface channel.
[0109] Example 3
[0110] Develop and validate more nanoDUBs for different polyubiquitin chain types
[0111] In addition to the nanoDUBs described in Example 2, more nanoDUBs will be designed, including those predicted to be selective for K11 (nanoCezanne), K29 / K33 (nanoTRABID), and Met1-linked linear chains (nanoOTULIN).
[0112] Western blot methods using ubiquitin chain-specific antibodies will be used to verify that nanoDUBs selectively eliminate the specific ubiquitin chains they are designed to target. The experiment will follow the format shown in Example 1. Q1-YFP and HERG-YFP will be co-expressed with individual nanoDUBs ± Nedd4-2 in HEK293 and CHO cells. The channels will be pulled down and their expression quantified by Western blotting. These blots will then be stripped and probed with ubiquitin chain-specific antibodies. Based on the results shown in Example 2, OTUD1 and OTUD4 are expected to selectively eliminate K63 and K48 chains, respectively. The experiment will determine whether more atypical chains (K6, K11, K29, K33, Met1) contribute to Q1 / HERG ubiquitination under basal or Nedd4-2 conditions. If so, the same experimental conditions can be used to verify the selectivity of nanoDUBs designed to target these chains. If not, we can increase the representation of these chains by co-expressing specific nanoHECTs. It is expected that these experiments will provide direct evidence that nanoDUBs act to clear the specific ubiquitin chain types they are designed to target.
[0113] Specific nanoDUBs will be deployed in cardiomyocytes to determine whether the functional effects observed in heterologous cells are transferable to the native context.
[0114] Example 4
[0115] NanoDUB can probe the regulation of Q1 and HERG by Nedd4-like E3 ligases
[0116] According to the results of Example 2, Nedd4-2 regulates Q1 mainly through K63 ubiquitin chains. However, in general, the exact type of ubiquitin chains conferred by a specific E3 ligase to a specific substrate and the function they confer in vivo are unknown, which is the case with several HECT E3 ligases. The Nedd4-like family of E3 ligases has 9 members, several of which have WW motifs that bind to PY motifs on substrate proteins. We will systematically compare how the co-expression of each of these Nedd4-like E3 ligases affects the surface density, total expression, and functional current of the Q1 / HERG channel. For those that measurably affect any aspect of channel behavior, we will co-express them with a single nanoDUB to gain insight into the type of ubiquitin chains they catalyze on the channel to affect its function. Overall, these experiments are expected to provide new insights into how different members of the Nedd4-like family of E3 ligases regulate the Q1 / HERG channel.
[0117] Example 5
[0118] Development of inducible nanoDUBs for spatio-temporal deubiquitination of Q1 and HERG
[0119] To develop a rapid inducible system, the catalytic domain of the selected DUB and the vhh4 nanobody will be fused to the rapamycin binding proteins FRB and FKBP, respectively. The inducible nanoDUB construct (FRB:DUB-P2A-CFP-P2A-FKBP:nano) will be created in three parts. First, the DUB catalytic domain will be amplified by PCR and the amplified fragment will be cloned into the FRBxx-P2A-CFP vector using AscI / AflII sites to create FRB:DUB-P2A-CFP. Second, we will use overlap extension PCR to create the P2A-FKBP:nano cassette, which will then be cloned downstream of CFP in the FRB:DUB-P2A-CFP construct using BglII / NotI sites to generate FRB:DUB-P2A-CFP-P2A-FKBP-nano.
[0120] To add spatial control to the inducible nanoDUBs, the above FKBP-nano constructs will be modified by the addition of subcellular targeting motifs (ER-KDEL; Golgi-GalT; plasma membrane-PH domain; endosome-FYVE motif). Spatio-temporal control of deubiquitination will allow us to infer whether enzymatic action in a specific subcellular localization is most important for the observed functional effects.
[0121] Example 6
[0122] NanoDUB can decipher the mechanism and rescue low [K + ] o- and antidepressant-induced HERG downregulation
[0123] Cells expressing HERG channels were exposed to low extracellular K + or the antidepressant desipramine, which resulted in a loss of ubiquitin-mediated surface access, which was attributed to enhanced endocytosis and reduced forward transport, respectively. NanoDUBs can be used to identify ubiquitination types that specifically involve two putatively distinct pathways (i.e., endocytosis versus forward transport). HEK293 cells expressing BBS-HERG-YFP ± a specific nanoDUB were exposed to low [K + ] o- (0.2 mM) or 30 µM desipramine for 6 h. Flow cytometry will be used to assess the ability of specific nanoDUBs to rescue HERG channel surface density and / or total expression. Additionally, Western blotting will be used to determine the relative proportions of the immature 135-kDa and fully glycosylated 155-kDa mature forms of HERG as a complementary approach to measure channel maturation and trafficking. Possible results could include: 1) specific distinct ubiquitin chain forms specify blocked forward trafficking or enhanced endocytosis; or alternatively 2) the same type of ubiquitin chain can mediate both effects, which would indicate that the subcellular region where ubiquitination occurs may be the dominant factor in specifying functional outcomes.
[0124] In addition to mechanistic insights, if nanoDUB can reverse the expression of surface HERG and I Kr Medium and low [K + ] o- or desipramine-induced decrease, this would provide a new drug target for preventing hypokalemia and antidepressant-induced exacerbation of LQTS.
[0125] Example 7
[0126] NanoDUB rescues a subset of LQT1 trafficking-defective mutants
[0127] Flow cytometric assays of channel surface density and total expression provide a rapid method to screen for the contribution of trafficking defects to various LQT1 mutant channels. This approach was previously used to show that homotetrameric Q1 channels containing the G589D LQT1 mutation exhibit a strong trafficking defect phenotype compared to wild-type channels (Aromolaran et al., 2014). This result is reproduced in the dot plots here, showing a reduction in the density of surface G589D compared to wild-type channels ( Figure 4B, C). Notably, co-expression of nanoOTUD1 substantially rescued the surface expression of the G589D channel ( Figure 4C In contrast, nanoOTUD1 was largely unable to rescue another transport-defective LQT1 mutation, V524G ( Figure 4D These results suggest that some transport defects in LQT1 mutations can be corrected by etching specific ubiquitin chains on the channel.
[0128] Example 8
[0129] NanoDUB rescues a subset of LQT2 trafficking-defective mutants
[0130] Flow cytometry approaches have also been used to evaluate trafficking-defective LQT2 mutants, and it has been shown that some of these mutants can be rescued by modulating the ubiquitin status of the channel. A comprehensive analysis of 167 LQT2-linked missense mutations was performed. Figure 5 Data from three LQT2 mutations from this study are shown, and it was found that two of them (K28E and Y43C) could be corrected by incubating cells at 27°C, while the other, C44F, could not be corrected by low temperature or the use of the pore blocker E-4031. Flow cytometry showed that the left shift in the histogram ( Figure 5 , top; black trace), all three mutants reduced the surface density of HERG. Culturing cells at 27°C rescued HERG surface expression in K28E and Y43C ( Figure 5 , top; cyan is shifted to the right compared to the black trace), but not the C44F mutant, which is consistent with previous studies. Excitingly, nanoOTUD1 also rescued some surface expression of Y43C and C44F (but not K28E) channels at 37°C. In addition to surface density, our approach also showed that Y43C reduced channel stability ( Figure 5 , bottom), and nanoOTUD1 increased the stability of the channel in all cases ( Figure 5 , bottom; right-shifted red trace). Overall, these results validate the use of the flow cytometry approach in these studies. Furthermore, the success of this initial attempt provides strong motivation to further explore the putative role of aberrant ubiquitination in multiple LQT2 missense mutations and to investigate which subsets can be rescued by modifying the ubiquitination status of HERG.
[0131] Example 9
[0132] Screening of multiple LQT1 and LQT2 missense mutations to discover a subset of transport-defective mutants that can be rescued by NanoDUB
[0133] The flow cytometry approach employed in Example 1 will be used to screen all identified LQT1 / LQT2 mutations. Begin by expressing 50 LQT1 and 50 LQT2 mutations randomly selected from a pool of pathogenic mutations distributed in different regions of each channel. For each mutation, the following will be quantified: severity of the transport defect (e.g., mean Alexa647 intensity compared to WT channels), effect on total expression (e.g., mean YFP signal compared to WT channels), and the effect of nanoOTUD1 on these parameters (by co-expressing the mutation and nanoOTUD1).
[0134] To identify specific mutations that altered the ubiquitination status in terms of the extent and / or phenotype of ubiquitin chains on the channel, ubiquitin chain-specific antibodies were used to determine if these mutations resulted in changes in the ubiquitination status of Q1 / HERG. For those mutations that resulted in a relative increase in K63 chains on the channel, they were further expressed in cardiomyocytes to confirm that similar changes occurred in the native background. Mass spectrometry analysis was also used.
[0135] Electrophysiological analysis will be performed on those mutants that can be “corrected” by co-expression with nanoOTUD1. First, it will be confirmed whether the corrected mutant channels express I Ks and I Kr Current. The mutant channels will be expressed under conditions identified from the above experiments that maximally rescue surface channels. Current amplitudes and key parameters (activation V 0.5 , activation and inactivation kinetics). Assessments will be performed in homo- and hetero-tetrameric channels characterized by co-expressed mutant and wild-type channels to mimic the autosomal dominant nature of most LQT1 / LQT2 conditions.
[0136] All patents, patent applications, and publications cited herein are incorporated by reference in their entirety, as if fully set forth herein.
[0137] The invention being thus described, it will be obvious that the invention may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications are intended to be included within the scope of the appended claims.
[0138] Citations
[0139] 1. Moss, A. J. & Kass, R. S. Long QT syndrome: from channels to cardiac arrhythmias. J Clin Invest 115, 2018 - 2024, doi:10.1172 / JCI25537(2005).
[0140] 2. Shimizu, W. The long QT syndrome: therapeutic implications of a genetic diagnosis. Cardiovasc Res 67, 347 - 356, doi:S0008 - 6363 (05) 00164 - 1[pii] 10.1016 / j.cardiores.2005.03.020 (2005).
[0141] 3. Tester, D. J., Will, M. L., Haglund, C. M. & Ackerman, M. J. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2, 507 - 517, doi:S1547 - 5271 (05) 00191 - 8 [pii] 10.1016 / j.hrthm.2005.01.020 (2005).
[0142] 4. Barhanin, J. et al. K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature 384, 78 - 80, doi:10.1038 / 384078a0 (1996).
[0143] 5. Sanguinetti, M. C. et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 384, 80 - 83, doi:10.1038 / 384080a0 (1996).
[0144] 6. Abbott, G. W. et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97, 175 - 187, doi:S0092 - 8674(00)80728 - X [pii] (1999).
[0145] 7. Curran, M. E. et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80, 795 - 803 (1995).
[0146] 8. Grilo, L. S., Carrupt, P. A. & Abriel, H. Stereoselective Inhibition of the hERG1 Potassium Channel. Front Pharmacol 1, 137, doi:10.3389 / fphar.2010.00137 (2010).
[0147] 9. George, A. L., Jr. Molecular and genetic basis of sudden cardiac death. J Clin Invest 123, 75 - 83, doi:62928 [pii] 10.1172 / JCI62928 (2013).
[0148] 10. Tester, D. J. & Ackerman, M. J. Cardiomyopathic and channelopathic causes of sudden unexplained death in infants and children. Annu Rev Med 60, 69 - 84, doi:10.1146 / annurev.med.60.052907.103838 (2009).
[0149] 11. Peroz, D. et al. Kv7.1 (KCNQ1) properties and channelopathies. J Physiol 586, 1785 - 1789, doi:10.1113 / jphysiol.2007.148254 (2008).
[0150] 12. Anderson, C. L. et al. Large - scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome. Nat Commun 5, 5535, doi:10.1038 / ncomms6535 (2014).
[0151] 13. Aromolaran, A. S., Subramanyam, P., Chang, D. D., Kobertz, W. R. & Colecraft, H. M. LQT1 mutations KCNQ1 C - terminus assembly domain suppress IKs using different mechanisms. Cardiovasc Res 104, 501 - 511, doi:10.1093 / cvr / cvu231 (2014).
[0152] 14. Kanki, H., Kupershmidt, S., Yang, T., Wells, S. & Roden, D. M. A structural requirement for processing the cardiac K+ channel KCNQ1. J Biol Chem 279, 33976 - 33983, doi:10.1074 / jbc.M404539200 [pii] (2004).
[0153] 15. Wiener, R. et al. The KCNQ1 (Kv7.1) COOH terminus, a multitiered scaffold for subunit assembly and protein interaction. J Biol Chem 283, 5815 - 5830, doi:10.1074 / jbc.M707541200 [pii] (2008).
[0154] 16. Hershko, A. & Ciechanover, A. The ubiquitin system. Annu Rev Biochem 67, 425 - 479, doi:10.1146 / annurev.biochem.67.1.425 (1998).
[0155] 17. Komander, D. The emerging complexity of protein ubiquitination. Biochem Soc Trans 37, 937 - 953, doi:10.1042 / BST0370937 (2009).
[0156] 18. Heride, C., Urbe, S. & Clague, M. J. Ubiquitin code assembly and disassembly. Curr Biol 24, R215 - 220, doi:10.1016 / j.cub.2014.02.002 (2014).
[0157] 19. Foot, N., Henshall, T. & Kumar, S. Ubiquitination and the Regulation of Membrane Proteins. Physiol Rev 97, 253 - 281, doi:10.1152 / physrev.00012.2016 (2017).
[0158] 20. MacGurn, J. A., Hsu, P. C. & Emr, S. D. Ubiquitin and membrane protein turnover: from cradle to grave. Annu Rev Biochem 81, 231 - 259, doi:10.1146 / annurev - biochem - 060210 - 093619 (2012).
[0159] 21. Mevissen, T. E. T. & Komander, D. Mechanisms of Deubiquitinase Specificity and Regulation. Annu Rev Biochem 86, 159 - 192, doi:10.1146 / annurev - biochem - 061516 - 044916 (2017).
[0160] 22. Mevissen, T. E. et al. OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell 154, 169 - 184, doi:10.1016 / j.cell.2013.05.046 (2013).
[0161] 23. Jespersen, T. et al. The KCNQ1 potassium channel is down - regulated by ubiquitylating enzymes of the Nedd4 / Nedd4 - like family. Cardiovasc Res 74, 64 - 74, doi:10.1016 / j.cardiores.2007.01.008 (2007).
[0162] 24. Krzystanek, K. et al. Deubiquitylating enzyme USP2 counteracts Nedd4-2-mediated downregulation of KCNQ1 potassium channels. Heart Rhythm 9, 440-448, doi:10.1016 / j.hrthm.2011.10.026 (2012).
[0163] 25. Albesa, M., Grilo, L. S., Gavillet, B. & Abriel, H. Nedd4-2-dependent ubiquitylation and regulation of the cardiac potassium channel hERG1. J Mol Cell Cardiol 51, 90-98, doi:10.1016 / j.yjmcc.2011.03.015 (2011).
[0164] 26. Hantouche, C. et al. Bag1 Co-chaperone Promotes TRC8 E3 Ligase-dependent Degradation of Misfolded Human Ether a Go-Go-related Gene (hERG) Potassium Channels. J Biol Chem 292, 2287-2300, doi:10.1074 / jbc.M116.752618 (2017).
[0165] 27. Iwai, C. et al. Hsp90 prevents interaction between CHIP and HERG proteins to facilitate maturation of wild-type and mutant HERG proteins. Cardiovasc Res 100, 520-528, doi:10.1093 / cvr / cvt200 (2013).
[0166] 28. Guo, J. et al. Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines. J Clin Invest 119, 2745 - 2757, doi:10.1172 / JCI39027 (2009).
[0167] 29. Massaeli, H., Guo, J., Xu, J. & Zhang, S. Extracellular K+ is a prerequisite for the function and plasma membrane stability of HERG channels. Circ Res 106, 1072 - 1082, doi:10.1161 / CIRCRESAHA.109.215970 (2010).
[0168] 30. Dennis, A. T., Nassal, D., Deschenes, I., Thomas, D. & Ficker, E. Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG. J Biol Chem 286, 34413 - 34425, doi:10.1074 / jbc.M111.254367 (2011).
[0169] 31. Kang, Y., Guo, J., Yang, T., Li, W. & Zhang, S. Regulation of the human ether-a-go-go-related gene (hERG) potassium channel by Nedd4 family interacting proteins (Ndfips). Biochem J 472, 71 - 82, doi:10.1042 / BJ20141282 (2015).
[0170] 32. Schneekloth, J. S., Jr. et al. Chemical genetic control of protein levels: selective in vivo targeted degradation. J Am Chem Soc 126, 3748 - 3754, doi:10.1021 / ja039025z (2004).
[0171] 33. Zhang, M. et al. Chaperoned ubiquitylation--crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex. Mol Cell 20, 525 - 538, doi:10.1016 / j.molcel.2005.09.023 (2005).
[0172] 34. Murata, S., Chiba, T. & Tanaka, K. CHIP: a quality-control E3 ligase collaborating with molecular chaperones. Int J Biochem Cell Biol 35, 572 - 578 (2003).
[0173] 35. Connell, P. et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 3, 93 - 96, doi:10.1038 / 35050618 (2001).
[0174] 36. Kubala, M. H., Kovtun, O., Alexandrov, K. & Collins, B. M. Structural and thermodynamic analysis of the GFP:GFP-nanobody complex. Protein Sci 19, 2389 - 2401, doi:10.1002 / pro.519 (2010).
[0175] 37. Wang, M. & Pickart, C. M. Different HECT domain ubiquitin ligases employ distinct mechanisms of polyubiquitin chain synthesis. EMBO J 24, 4324-4333, doi:10.1038 / sj.emboj.7600895 (2005).
[0176] 38. Wang, M., Cheng, D., Peng, J. & Pickart, C. M. Molecular determinants of polyubiquitin linkage selection by an HECT ubiquitin ligase. EMBO J 25, 1710-1719, doi:10.1038 / sj.emboj.7601061 (2006).
[0177] 39. Scialpi, F. et al. Itch self-polyubiquitylation occurs through lysine-63 linkages. Biochem Pharmacol 76, 1515-1521, doi:10.1016 / j.bcp.2008.07.028 (2008).
[0178] 40. Ogunjimi, A. A. et al. The ubiquitin binding region of the Smurf HECT domain facilitates polyubiquitylation and binding of ubiquitylated substrates. J Biol Chem 285, 6308-6315, doi:10.1074 / jbc.M109.044537 (2010).
[0179] 41. Kim, H. C. & Huibregtse, J. M. Polyubiquitination by HECT E3s and the determinants of chain type specificity. Mol Cell Biol 29, 3307-3318, doi:10.1128 / MCB.00240-09 (2009).
[0180] 42. Scheffner, M. & Kumar, S. Mammalian HECT ubiquitin-protein ligases: biological and pathophysiological aspects. Biochim Biophys Acta 1843, 61-74, doi:10.1016 / j.bbamcr.2013.03.024 (2014).
[0181] 43. Michel, M. A. et al. Assembly and specific recognition of k29- and k33-linked polyubiquitin. Mol Cell 58, 95-109, doi:10.1016 / j.molcel.2015.01.042 (2015).
[0182] 44. Matsumoto, M. L. et al. K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. Mol Cell 39, 477-484, doi:10.1016 / j.molcel.2010.07.001 (2010).
[0183] 45. Newton, K. et al. Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134, 668-678, doi:10.1016 / j.cell.2008.07.039 (2008).
[0184] 46. Crabtree, G. R. & Schreiber, S. L. Three-part inventions: intracellular signaling and induced proximity. Trends Biochem Sci 21, 418 - 422, doi:S0968-0004 (96) 20027-1 [pii] (1996).
[0185] 47. Inoue, T., Heo, W. D., Grimley, J. S., Wandless, T. J. & Meyer, T. An inducible translocation strategy to rapidly activate and inhibit small GTPase signaling pathways. Nat Methods 2, 415 - 418, doi:nmeth763 [pii]10.1038 / nmeth763 (2005).
[0186] 48. Yang, T., Suhail, Y., Dalton, S., Kernan, T. & Colecraft, H. M. Genetically encoded molecules for inducibly inactivating CaV channels. Nat Chem Biol 3, 795 - 804, doi:nchembio.2007.42 [pii] 10.1038 / nchembio.2007.42(2007).
[0187] 49. Stornaiuolo, M. et al. KDEL and KKXX retrieval signals appended to the same reporter protein determine different trafficking between endoplasmic reticulum, intermediate compartment, and Golgi complex. Mol Biol Cell 14, 889 - 902, doi:10.1091 / mbc.E02-08-0468 (2003).
[0188] 50.Lee, S.A. Targeting of the FYVE domain to endosomal membranesis regulated by a histidine switch. Proc Natl Acad Sci USA 102, 13052–13057.
[0189] 51.Maffucci, T. & Falasca, M. Specificity in pleckstrin homology (PH)domain membrane targeting: a role for a phosphoinositide-protein co-operativemechanism. FEBS Lett 506, 173–179.
[0190] 52.Mevissen, TET activity Molecular basis of Lys11-polyubiquitinspecificity in the deubiquitinase Cezanne. Nature 538, 402–405, doi:10.1038 / nature19836 (2016).
[0191] 53.Damgaard, RB Activity The Deubiquitinase OTULIN Is an EssentialNegative Regulator of Inflammation and Autoimmunity. Cell 166, 1215–1230e1220, doi:10.1016 / j.cell.2016.07.019 (2016).
[0192] 54.Ordureau , A. , Munch , C. & Harper , JW Quantifying ubiquitin signaling . Mol Cell 58, 660–676, doi:10.1016 / j.molcel.2015.02.020 (2015).
Claims
1. A recombinantly engineered deubiquitinase (DUB), comprising: a) Catalytic unit; b) protein binders; and c) a variable linker between the catalytic unit and the protein binder.
2. The recombinant engineered DUB of claim 1, wherein the catalytic unit is selective or non-selective.
3. The recombinant engineered DUB of claim 1, wherein the catalytic unit comprises a catalytic domain of a deubiquitinating enzyme selected from the group consisting of the ubiquitin-specific protease (USP) family, the ovarian tumor protease (OTU) family, the ubiquitin C-terminal hydrolase (UCH) family, the Josephin domain family (Josephin), the novel DUB family containing a motif that interacts with ubiquitin (MINDY), and the JAB1 / MPN / Mov34 metalloenzyme domain family (JAMM).
4. The recombinant engineered DUB of claim 3, wherein the catalytic unit comprises a catalytic domain of a deubiquitinating enzyme from the USP family.
5. The recombinant engineered DUB of claim 4, wherein the catalytic unit comprises the catalytic domain of USP21.
6. The recombinant engineered DUB of claim 3, wherein the catalytic unit comprises a catalytic domain of a deubiquitinating enzyme from the OTU family.
7. The recombinant engineered DUB of claim 6, wherein the catalytic unit comprises the catalytic domain of OTUD1.
8. The recombinant engineered DUB of claim 6, wherein the catalytic unit comprises the catalytic domain of OTUD4.
9. The recombinant engineered DUB of claim 6, wherein the catalytic unit comprises the catalytic domain of Cezanne.
10. The recombinant engineered DUB of claim 6, wherein the catalytic unit comprises the catalytic domain of TRABID.
11. The recombinant engineered DUB of claim 6, wherein the catalytic unit comprises the catalytic domain of OTULIN.
12. The recombinant engineered DUB of claim 1, wherein the protein binder is selected from the group consisting of an intrabody fragment, a scFv, a nanobody, an antibody mimetic, a monoclonal antibody, a DARPin, a lipocalin, and a targeting sequence.
13. The recombinant engineered DUB of claim 12, wherein the protein binder is a vhh4 nanobody.
14. The recombinant engineered DUB of claim 1, wherein the catalytic unit is the catalytic domain of USP21, and the protein binder is the vhh4 nanobody, and the resulting recombinant engineered deubiquitinase (nanoUSP21) is capable of non-selectively eliminating all linkage types.
15. The recombinant engineered DUB of claim 1, wherein the catalytic unit is the catalytic domain of OTUD1, and the protein binder is the vhh4 nanobody, and the resulting recombinant engineered deubiquitinase (nanoOTUD1) is capable of selectively eliminating K63 linkages.
16. The recombinant engineered DUB of claim 1, wherein the catalytic unit is the catalytic domain of OTUD4, and the protein binder is the vhh4 nanobody, and the resulting recombinant engineered deubiquitinase (nanoOTUD4) is capable of selectively eliminating K48 linkages.
17. The recombinant engineered DUB of claim 1, wherein the catalytic unit is the catalytic domain of Cezanne and the protein binder is the vhh4 nanobody, and the resulting recombinant engineered deubiquitinase (nanoCezanne) is capable of selectively eliminating K11 linkages.
18. The recombinant engineered DUB of claim 1, wherein the catalytic unit is the catalytic domain of TRABID and the protein binder is the vhh4 nanobody, and the resulting recombinant engineered deubiquitinase (nanoTRABID) is capable of selectively eliminating K29 and / or K33 linkages.
19. The recombinant engineered DUB of claim 1, wherein the catalytic unit is the catalytic domain of OTULIN, and the protein binder is the vhh4 nanobody, and the resulting recombinant engineered deubiquitinase (nanoOTULIN) is capable of selectively eliminating Met1 linkages.
20. A recombinant expression vector comprising a nucleic acid encoding the recombinantly engineered DUB of claim 1.
21. A cell transformed with the vector of claim 20.
22. The cell of claim 21, wherein the cell is mammalian or bacterial.
23. A method of treating or ameliorating the effects of an inherited ion channelopathy in a subject, comprising administering to the subject a nucleic acid encoding the recombinant engineered DUB of claim 1.
24. The method of claim 23, wherein the subject is a mammal.
25. The method of claim 24, wherein the subject is a human.
26. The method of claim 23, wherein the inherited ion channelopathy is selected from the group consisting of epilepsy, migraine, neuropathic pain, cardiac arrhythmia, long QT syndrome, Brugada syndrome, cystic fibrosis, diabetes, hyperinsulinemic hypoglycemia, Bartter syndrome, and diabetes insipidus.
27. The method of claim 26, wherein the inherited ion channelopathy is long QT syndrome and the recombinantly engineered DUB is nanoOTUD1.
28. A method for screening mutations causing inherited ion channel diseases for transport defect mutations that can be treated by the recombinantly engineered DUB of claim 1, wherein The following steps are involved: a) Measure the surface density and / or total expression of mutant channels in cells expressing mutations causing inherited channelopathies; b) if the surface density and / or total expression of the mutant channel is reduced relative to the wild-type (WT) channel, determining the ubiquitination status of the mutant channel; c) selecting a recombinant engineered DUB of claim 1 and co-expressing it with the mutation based on the ubiquitination status of the mutant channel, and then measuring the surface density and / or total expression of the mutant channel in cells with the co-expression; and d) If the surface density and / or total expression of the mutant channel is restored relative to the WT channel in step (c), then the mutation is identified as treatable.
29. The method of claim 28, wherein the inherited ion channelopathy is selected from the group consisting of epilepsy, migraine, neuropathic pain, cardiac arrhythmia, long QT syndrome, Brugada syndrome, cystic fibrosis, diabetes, hyperinsulinemic hypoglycemia, Bartter syndrome, and diabetes insipidus.
30. The method of claim 29, wherein the inherited ion channelopathy is long QT syndrome.
31. A method of treating or ameliorating the effects of an acute / chronic viral infection in a subject, comprising administering to the subject a nucleic acid encoding the recombinant engineered DUB of claim 1.
32. The method of claim 31, wherein the subject is a mammal.
33. The method of claim 32, wherein the subject is a human.
